CL2011001178A1 - Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. - Google Patents

Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.

Info

Publication number
CL2011001178A1
CL2011001178A1 CL2011001178A CL2011001178A CL2011001178A1 CL 2011001178 A1 CL2011001178 A1 CL 2011001178A1 CL 2011001178 A CL2011001178 A CL 2011001178A CL 2011001178 A CL2011001178 A CL 2011001178A CL 2011001178 A1 CL2011001178 A1 CL 2011001178A1
Authority
CL
Chile
Prior art keywords
carboxamide
thiophene
chloro
salt
niquinuclidin
Prior art date
Application number
CL2011001178A
Other languages
English (en)
Inventor
Gerhard Koenig
Richard Chesworth
Gideon Shapiro
Original Assignee
Forum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forum Pharmaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Publication of CL2011001178A1 publication Critical patent/CL2011001178A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Procedimiento para mejorar la cognición que comprende administrar (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal de la misma a una dosis inferior a 3 mg; composición farmacéutica de dosis unitaria.
CL2011001178A 2008-11-19 2011-05-19 Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. CL2011001178A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11610608P 2008-11-19 2008-11-19

Publications (1)

Publication Number Publication Date
CL2011001178A1 true CL2011001178A1 (es) 2011-10-14

Family

ID=41786120

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2011001178A CL2011001178A1 (es) 2008-11-19 2011-05-19 Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
CL2017001853A CL2017001853A1 (es) 2008-11-19 2017-07-18 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016).
CL2018001420A CL2018001420A1 (es) 2008-11-19 2018-05-25 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2017001853A CL2017001853A1 (es) 2008-11-19 2017-07-18 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016).
CL2018001420A CL2018001420A1 (es) 2008-11-19 2018-05-25 Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)

Country Status (35)

Country Link
US (6) US8642638B2 (es)
EP (4) EP2540297B1 (es)
JP (6) JP5272080B2 (es)
KR (3) KR20180011888A (es)
CN (3) CN105687190A (es)
AU (1) AU2009316557B2 (es)
BR (1) BRPI0922057A2 (es)
CA (3) CA3017886A1 (es)
CL (3) CL2011001178A1 (es)
CO (1) CO6400190A2 (es)
CR (1) CR20110267A (es)
CY (3) CY1113671T1 (es)
DK (3) DK2540297T3 (es)
EC (1) ECSP11011076A (es)
ES (3) ES2541528T3 (es)
HK (1) HK1158520A1 (es)
HR (3) HRP20130007T1 (es)
HU (2) HUE037938T2 (es)
IL (5) IL212921A (es)
LT (1) LT2889033T (es)
MX (1) MX2011005270A (es)
MY (2) MY173229A (es)
NZ (2) NZ593467A (es)
PE (1) PE20110711A1 (es)
PH (2) PH12014501629B1 (es)
PL (3) PL2889033T3 (es)
PT (3) PT2355822E (es)
RS (1) RS52583B (es)
RU (3) RU2532327C2 (es)
SG (1) SG10201504102QA (es)
SI (3) SI2540297T1 (es)
SM (2) SMT201300003B (es)
TR (1) TR201807944T4 (es)
WO (1) WO2010059844A1 (es)
ZA (1) ZA201104044B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012074799A1 (en) * 2010-11-18 2012-06-07 Envivo Pharmaceuticals, Inc. Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
EP2706854A4 (en) * 2011-05-09 2014-12-03 Envivo Pharmaceuticals Inc TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
MX2014000146A (es) * 2011-07-01 2014-02-19 Envivo Pharmaceuticals Inc Metodos de tratamiento del deterioro cognitivo limitado.
AU2013259871A1 (en) * 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JP7170670B2 (ja) 2017-02-27 2022-11-14 ユニヴァーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイアー エデュケイション 抗精神病組成物及び治療方法
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3731749A4 (en) 2017-12-31 2022-07-27 Neuroenhancement Lab, LLC NEURO-ACTIVATION SYSTEM AND METHOD FOR ENHANCING EMOTIONAL RESPONSE
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CA3112564A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0405617A3 (en) 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de) 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
ZA889166B (en) 1987-12-10 1990-05-30 Duphar Int Res 1,7-annelated indolecarboxylic acid esters and -amides
US5198437A (en) 1987-12-10 1993-03-30 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and amides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5114947A (en) 1990-12-27 1992-05-19 Erbamont Inc. Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de) 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
ATE192157T1 (de) 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL132437A0 (en) 1997-05-30 2001-03-19 Neurosearch As 8-Azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
AU6394399A (en) 1998-09-18 2000-04-10 Rockefeller University, The Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en) 1999-11-08 2002-07-09 Research Triangle Institute Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
WO2001040261A1 (en) 1999-12-01 2001-06-07 Ortho-Mcneil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
CA2393538A1 (en) 1999-12-14 2001-06-21 Pharmacia & Upjohn Company Human ion channels
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AU2001252463A1 (en) 2000-06-06 2001-12-17 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr) 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
DE10044905A1 (de) 2000-09-12 2002-03-21 Merck Patent Gmbh (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003018586A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2003081978A (ja) 2001-09-10 2003-03-19 Mitsubishi Pharma Corp スピロ環式化合物およびその医薬用途
BR0212477A (pt) 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
CA2462453C (en) 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA04003986A (es) 2001-10-26 2004-07-23 Upjohn Co Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr.
MXPA04004464A (es) 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
CA2466344A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
FR2832714B1 (fr) 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
US7067261B2 (en) 2001-12-14 2006-06-27 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10162442A1 (de) 2001-12-19 2003-07-03 Bayer Ag Monocyclische N-Aryl-amide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003070728A2 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
US6894042B2 (en) 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1478646A1 (en) 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003267174A1 (en) 2002-05-09 2003-11-11 Memory Pharmaceuticals Corporation Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
MXPA05000754A (es) 2002-07-17 2005-04-19 Warner Lambert Co Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib.
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
JP2006503008A (ja) 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP1543000B1 (en) 2002-09-25 2013-03-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
PL377777A1 (pl) 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA05010496A (es) 2003-03-28 2005-11-16 Pharmacia & Upjohn Co Llc Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP1824848A1 (en) 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP4995075B2 (ja) 2004-03-25 2012-08-08 メモリー・ファーマシューティカルズ・コーポレイション インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
WO2007038367A1 (en) 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
CA2705296A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
EP2285374B1 (en) 2008-04-29 2019-09-18 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
NZ589309A (en) 2008-04-29 2012-03-30 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
PT2282778T (pt) 2008-04-29 2017-04-27 Pharnext Novas abordagens terapêuticas no tratamento da doença de alzheimer e doenças relacionadas através de uma modulação da angiogénese
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
WO2010075635A1 (en) 2008-12-30 2010-07-08 Ramot At Tel Aviv University Ltd. Combination therapies using nap
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
NZ594776A (en) 2009-02-26 2013-05-31 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US8404711B2 (en) 2009-04-13 2013-03-26 Theravance, Inc. 5-HT4 receptor agonist compounds for treatment of cognitive disorders
CN102548986A (zh) 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions

Also Published As

Publication number Publication date
EP2355822A1 (en) 2011-08-17
PH12018500023A1 (en) 2019-07-15
RU2014122858A (ru) 2015-12-10
EP2355822B1 (en) 2012-10-10
CO6400190A2 (es) 2012-03-15
US20110288119A1 (en) 2011-11-24
MY159826A (en) 2017-02-15
NZ593467A (en) 2013-07-26
PT2355822E (pt) 2013-01-14
US20130137717A1 (en) 2013-05-30
ES2673016T3 (es) 2018-06-19
PE20110711A1 (es) 2011-10-11
DK2889033T3 (en) 2018-07-02
CY1113671T1 (el) 2016-07-27
IL256313A (en) 2018-02-28
CA2894860C (en) 2018-11-06
EP2540297B1 (en) 2015-04-08
CY1116460T1 (el) 2017-03-15
DK2540297T3 (en) 2015-07-13
PH12014501629A1 (en) 2016-01-18
HK1158520A1 (en) 2012-07-20
US20150265583A1 (en) 2015-09-24
LT2889033T (lt) 2018-07-10
EP2889033B1 (en) 2018-03-21
RU2011124515A (ru) 2012-12-27
JP2015083574A (ja) 2015-04-30
HUE026815T2 (en) 2016-07-28
SI2889033T1 (en) 2018-08-31
TR201807944T4 (tr) 2018-06-21
JP5869653B2 (ja) 2016-02-24
EP2540297A1 (en) 2013-01-02
CA3017886A1 (en) 2010-05-27
SI2540297T1 (sl) 2015-08-31
PT2889033T (pt) 2018-06-18
IL212921A0 (en) 2011-07-31
IL212921A (en) 2015-11-30
AU2009316557A1 (en) 2010-05-27
CN102281878A (zh) 2011-12-14
MX2011005270A (es) 2011-08-03
EP3357495B1 (en) 2019-12-25
SMT201300003B (it) 2013-05-06
ECSP11011076A (es) 2011-09-30
HUE037938T2 (hu) 2018-09-28
KR20180011888A (ko) 2018-02-02
PT2540297E (pt) 2015-08-26
CN105687191A (zh) 2016-06-22
CL2017001853A1 (es) 2018-05-11
EP2889033A1 (en) 2015-07-01
IL256140A (en) 2018-02-28
ES2396300T3 (es) 2013-02-20
PL2355822T3 (pl) 2013-03-29
HRP20130007T1 (hr) 2013-01-31
JP2016128442A (ja) 2016-07-14
BRPI0922057A2 (pt) 2015-12-15
PL2889033T3 (pl) 2018-10-31
HRP20180942T1 (hr) 2018-08-10
EP3357495A1 (en) 2018-08-08
MY173229A (en) 2020-01-07
US20180271844A1 (en) 2018-09-27
US20140148479A1 (en) 2014-05-29
IL242034A (en) 2017-12-31
NZ613291A (en) 2014-11-28
JP2012509347A (ja) 2012-04-19
JP5272080B2 (ja) 2013-08-28
JP2013166771A (ja) 2013-08-29
CN105687190A (zh) 2016-06-22
JP2018039818A (ja) 2018-03-15
CA2744278C (en) 2015-09-08
JP2020040977A (ja) 2020-03-19
KR20140146216A (ko) 2014-12-24
RU2662560C2 (ru) 2018-07-26
US8569354B2 (en) 2013-10-29
IL242034A0 (en) 2015-11-30
AU2009316557B2 (en) 2015-08-27
SMT201500167B (it) 2015-09-07
CR20110267A (es) 2011-10-13
PL2540297T3 (pl) 2015-12-31
US8642638B2 (en) 2014-02-04
SG10201504102QA (en) 2015-06-29
US8815933B2 (en) 2014-08-26
CL2018001420A1 (es) 2018-09-28
DK2355822T3 (da) 2013-01-28
RS52583B (en) 2013-04-30
RU2018125456A (ru) 2020-01-13
JP6223480B2 (ja) 2017-11-01
CA2894860A1 (en) 2010-05-27
PH12014501629B1 (en) 2016-01-18
SI2355822T1 (sl) 2013-02-28
JP5674854B2 (ja) 2015-02-25
IL242035A0 (en) 2015-11-30
ES2541528T3 (es) 2015-07-21
CA2744278A1 (en) 2010-05-27
WO2010059844A1 (en) 2010-05-27
RU2532327C2 (ru) 2014-11-10
US20140155430A1 (en) 2014-06-05
CY1121607T1 (el) 2020-05-29
ZA201104044B (en) 2012-11-28
HRP20150711T1 (hr) 2015-08-14
KR20110091549A (ko) 2011-08-11

Similar Documents

Publication Publication Date Title
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2011002847A1 (es) Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion.
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
PE20212245A1 (es) Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2011001927A1 (es) Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"